This problem has been featured in a cover story in The Economist (Anonymous 2013) and has attracted the attention of the NIH leaders (Collins and Tabak 2014). 2011), and investigators at Amgen were able to reproduce only 6 of 53 studies in basic cancer biology despite often cooperating with the original investigators (Begley and Ellis 2012). Investigators at Bayer Healthcare were reportedly able to reproduce only 20–25 % of 67 preclinical studies (Prinz et al. In fact, the reproducibility of a large percentage of published findings has been questioned. Ideally, any experienced investigator with the right tools should be able to reproduce a finding published in a peer-reviewed biomedical science journal.
0 kommentar(er)
